Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

China Molecular Diagnostic Market, Test Volume & Forecast

Renub Research
Posted on: 22 Sep 17
China Molecular Diagnostic Market, Test Volume & Forecast

Access Full Research: http://www.renub.com/china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php

 

Get Free 10% Customization in this Report.

China molecular diagnostics market is growing at a fast pace owing to rising prevalence of infectious diseases and cancer cases in the region coupled with growing geriatric population. It is projected that China molecular diagnostics market will exceed US$ 1.5 Billion by the end of 2022. Molecular diagnostics are extremely effective in diagnosing and preventing diseases, offering accurate and precise healthcare interventions in the early stages of diseases.


China Molecular Diagnostics Segments Market

China molecular diagnostics market has been segmented into three major categories: Oncology Testing, Infectious Disease Testing and Genetic Disease Testing. Further, Oncology Testing has been segmented into three major categories: Breast Cancer Testing, Colorectal Cancer Testing and Prostate Cancer Testing. Infectious Disease Testing has been segmented into two major categories, namely, virology and HPV and Genetic Testing has been segmented into Blood Screening and HLA.

China Infectious Disease test market; Virology tests accounts for the highest market share. Furthermore, our analysis found that nearly 300 million molecular diagnostic tests will be performed in China by the end of 2022 of which Virology accounts for one of the most performed tests segments.

Increasing incidence of contagious diseases along with cancer cases and the rise of the private healthcare sector in China, with the development of socio-economic conditions and the growth of a wealthy middle class, has increased the quest for affordable and quality healthcare across the region are some of the contributors which are anticipated to drive the molecular diagnostics market over the forecast period.

This is the 5th report on Molecular Diagnostics industry published by Renub Research. This report titled “China Molecular Diagnostics Market, Test Volume & Forecast by Oncology Test (Breast Cancer, Colorectal Cancer, Prostate Cancer) Infectious Disease Test (Virology, HPV), Genetic Test (Blood Screening, HLA)” provides a comprehensive assessment of the fast–evolving, high–growth China Molecular diagnostics market. This 105 page report with 55 Figures and 14 Tables studies the China Molecular Diagnostic market from 4 view points: 

1. Market & Forecast 
2. Molecular Diagnostics Segments Market & Forecast
3. Molecular Diagnostics Segments Test Volume & Forecast 
4. Profiles of Select Private Clinical Labs & Diagnostic Services Companies 

Segments Covered in this report are as follows:

Oncology Test Market and Volume

• Breast Cancer
• Colorectal Cancer
• Prostate Cancer

Infectious Disease Test Market and Volume

• Virology
• HPV

Genetic Test Market and Volume

• Blood Screening 
• HLA

Key Players Analysis

• Zhejiang Di’an Diagnostics Technology Co., Ltd.
• ADICON Clinical Laboratories (Privately held)
• Guangzhou Kingmed Diagnostics Center Co. Ltd.
• Kindstar Global (Privately held)
• BGI–Shenzhen
• OriGene Technologies    

Key questions answered in the study

• What is China molecular diagnostics market size from 2011 to 2022?
• What is China molecular diagnostics tests volume from 2011 to 2022?
• What are China molecular diagnostics segments market & Forecast? 
• What are the growth drivers of Molecular diagnostics in China?

 

Content from Old Report is given below:

The user can buy this report in Chapters from Purchase by Chapter section given above

 

China Molecular Diagnostics Market Overview
 
China Molecular Diagnostics is a Billion dollar industry and its growing year on year rapidly. Molecular diagnostics holds immense potential in future of China Diagnostics Sector. It is predicted that China will perform over 300 Million molecular diagnostic tests during the forecasting period 2015 – 2019. Infectious disease and Oncology Testing both have almost equal share in China Molecular Diagnostics Sector. However in further sub–segmenting of molecular diagnostics market share perspective Virology Cancer Test holds the highest market share followed by Colorectal cancer and Breast Cancer Test.     

Rising demand from middle class for high quality healthcare products, rapid development in the diagnosis of infectious diseases and increasing number of private hospitals are some of the growth drivers which is fueling this sector. However industry faces some kind of challenges such as shortage of lab technicians, lack of expertise in advanced technology in the local companies etc.

This is the 5th report on Molecular Diagnostics industry published by Renub Research. This report titled “China Molecular Diagnostics Market, Test Volume & Forecast” provides a comprehensive assessment of the fast–evolving, high–growth China Molecular diagnostics market. This 84 page report with 55 Figures and 13 Tables studies the China Molecular Diagnostic market from 4 view points:

1)  Market & Forecast
2)  Application Wise Market & Forecast
3)  Application Wise Test Volume & Forecast
4)  Profiles of Select Private Clinical Labs & Diagnostic Services Companies

 

Contact Us

Rajat Gupta

Sr. Marketing Manager

Email: info@renub.com

Phone: +1-678-302-0700

Web: www.renub.com

For more information:
www.renub.com/china-molecular-diagnostics-market-test-volume-and-forecast-491-p.php

Editor's Details

Rajat Gupta
Renub Research
www.renub.com
6783020700
rajat.gupta@renub.com

Last updated on: 22/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.